Gomes Francisca L, Jeong Seol-Ha, Shin Su Ryon, Leijten Jeroen, Jonkheijm Pascal
Department of Molecules and Materials, Laboratory of Biointerface Chemistry, Faculty of Science and Technology, Technical Medical Centre and MESA+ Institute, University of Twente, Drienerlolaan 5, Enschede, 7522NB,The Netherlands.
Department of Developmental BioEngineering, Leijten Laboratory, Faculty of Science and Technology, Technical Medical Centre, University of Twente, Drienerlolaan 5, Enschede, 7522NB, The Netherlands.
Adv Funct Mater. 2024 Jul 10;34(28). doi: 10.1002/adfm.202315879. Epub 2024 Feb 8.
Blood scarcity is one of the main causes of healthcare disruptions worldwide, with blood shortages occurring at an alarming rate. Over the last decades, blood substitutes has aimed at reinforcing the supply of blood, with several products (e.g., hemoglobin-based oxygen carriers, perfluorocarbons) achieving a limited degree of success. Regardless, there is still no widespread solution to this problem due to persistent challenges in product safety and scalability. In this Review, we describe different advances in the field of blood substitution, particularly in the development of artificial red blood cells, otherwise known as engineered erythrocytes. We categorize the different strategies into natural, synthetic, or hybrid approaches, and discuss their potential in terms of safety and scalability. We identify synthetic engineered erythrocytes as the most powerful approach, and describe erythrocytes from a materials engineering perspective. We review their biological structure and function, as well as explore different methods of assembling a material-based cell. Specifically, we discuss how to recreate size, shape, and deformability through particle fabrication, and how to recreate the functional machinery through synthetic biology and nanotechnology. We conclude by describing the versatile nature of synthetic erythrocytes in medicine and pharmaceuticals and propose specific directions for the field of erythrocyte engineering.
血液短缺是全球医疗保健中断的主要原因之一,血液短缺正以惊人的速度发生。在过去几十年里,血液替代品旨在加强血液供应,一些产品(如基于血红蛋白的氧载体、全氟化碳)取得了有限的成功。尽管如此,由于产品安全性和可扩展性方面的持续挑战,这个问题仍然没有广泛适用的解决方案。在本综述中,我们描述了血液替代领域的不同进展,特别是在人工红细胞(也称为工程红细胞)的开发方面。我们将不同的策略分为天然、合成或混合方法,并从安全性和可扩展性方面讨论它们的潜力。我们将合成工程红细胞确定为最有效的方法,并从材料工程的角度描述红细胞。我们回顾它们的生物学结构和功能,并探索组装基于材料的细胞的不同方法。具体来说,我们讨论如何通过颗粒制造来重现大小、形状和可变形性,以及如何通过合成生物学和纳米技术来重现功能机制。我们通过描述合成红细胞在医学和制药领域的多功能性质来结束本文,并为红细胞工程领域提出具体方向。